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Abstract
Intravenous albumin is recommended for hepatorenal disorders (HRD), but individuals who do not recover renal function may be
at a high risk for pulmonary edema.We reviewed outcomes by the amount of albumin infused in 93 patients not receiving dialysis at
admission but being treated with intravenous albumin for acute HRD at our institution. Absence of renal recovery was deﬁned as
no decrease in serum creatinine and requirement of dialysis during hospitalization, and partial renal recovery was deﬁned as a
decrease in serum creatinine but not to prehospitalization levels. Associations of clinical factors including total albumin infused,
presence of renal recovery, and oliguria with the development of pulmonary edema during hospitalization were determined using
logistic regression. Of the 93 patients, 20 patients had complete renal recovery, 17 patients had partial renal recovery, and 56
patients showed no renal recovery. Most patients received 300–600 g of albumin. Overall, 47.3% of patients developed pulmonary
edema (n=44), but the risk was 75% in patients with oliguria on presentation and no renal recovery versus 17% in those with no
oliguria and complete renal recovery (P<0.001). In the logistic regression model, oliguria (3.32; 95% conﬁdence interval [CI]:
1.12, 9.81) and no renal recovery (3.38; 95%CI: 1.24, 9.16) were each associated with higher odds of pulmonary edema after adjust-
ment for covariates. No association was noted between total albumin infused and pulmonary edema. In summary, absence of renal
recovery and oliguria in patients with HRD receiving intravenous albumin is associated with a higher risk of pulmonary edema.
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Introduction
Intravenous albumin plus midodrine and octreotide are
recommended for the treatment of type I hepatorenal syn-
drome (HRS) (1). In clinical practice, albumin use is not
just limited to type I HRS and is used in the setting of any
acute renal failure (ARF) with underlying cirrhosis (hepator-
enal disorders, or HRD) for volume expansion. In 1996, the
International Club of Ascites proposed a deﬁnition and diag-
nostic criteria for HRS (2), which was later revised in 2007
with albumin replacing normal saline for volume replacement
(3). The recommended dose of albumin for volume resuscita-
tion is 1 g/kg of body weight per day with up to a maximum of
100 g/day; however, the evidence for this threshold is not sup-
ported by clinical trials. Volume resuscitation with albumin
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infusions in cirrhosis is expected to increase total body volume
and circulatory function with resultant improvement in renal
function (4). It is also thought to reduce the formation of
ascites and edema by increasing the microvascular oncotic
pressure, but the pathophysiological basis and evidence sup-
porting this remains controversial (5, 6).
The distribution of infused albumin between intravascular
and extravascular compartments depends on the transcapil-
lary membrane permeability, which is dependent on multiple
factors, including intravascular volume status, and comorbid
conditions such as hypertension, diabetes, heart failure, and
infections (7, 8). Studies involving human volunteers have
shown that rapid increases in plasma volume that occur imme-
diately with albumin infusions are not seen with repeated
infusions despite increasing serum albumin levels (9). Most
importantly, response to albumin infusions varies across indivi-
duals with cirrhosis, and intravascular volume does not consis-
tently rise in all cirrhotic patients (10, 11). Earlier studies have
reported cases of increasing pleural effusions, development of
pulmonary edema, and heart failure and rupture of esopha-
geal varices with albumin infusions in cirrhotic patients
(12). However, recent guidelines (1, 13) poorly address the
potential side effects of continued albumin infusions in cir-
rhotic patients with compromised renal function, where
volume status is difﬁcult to determine. We retrospectively
reviewed the incidence of new onset pulmonary edema as
well as patient outcomes in cirrhotic patients who received
albumin infusions as part of the treatment for acute HRD
at our university medical center. We hypothesized that oli-
guria is associated with a signiﬁcantly increased risk of pul-
monary edema in patients with HRD receiving intravenous
albumin.
Materials and Methods
Study population
We conducted a retrospective chart review of all cirrhotic
patients who were admitted to our institution between 2011
and 2013 with ARF and received albumin as part of manage-
ment of acute HRD. Diagnostic codes (ICD-9) for cirrhosis
(571, 571.2, 571.5, and 571.6), HRS (572.4), and ARF (584
and 584.9) were used to identify patients for the study. All
identiﬁed charts were then manually reviewed to conﬁrm
the diagnosis of cirrhosis and ARF and that albumin was
given as part of management of acute HRD (veriﬁed by phy-
sician documentation in chart). A total of 115 cirrhotic
patients who were admitted between January 2011 and
December 2013 were identiﬁed. After excluding patients
who had an abnormal chest x-ray (CXR), were intubated
or were dialysis dependent at admission, or were transferred
to another hospital for care, a total of 93 patients were
included in the ﬁnal analysis. All 93 patients had clinically
attributed HRD as the etiology of ARF, with no evidence
of urinary tract obstruction or primary glomerular disease
by clinical criteria. The study was approved by the Institutional
Review Board of Loyola University Chicago’s Health
Sciences Campus.
Information collected from the electronic medical record
included age, sex, cause of liver disease, Model for End-Stage
Liver Disease (MELD) score, serum creatinine at admission
and at 72 hours after admission, urine output (UOP) during
the ﬁrst 24 hours of hospitalization, urine electrolytes before
and after treatment, dialysis start date, presence of pulmon-
ary edema on CXR, total amount of albumin administered
during the hospital stay and prior to the development of
pulmonary edema, and need for endotracheal intubation.
Albumin infusions contained 4% albumin at initial presentation
and 25% albumin at subsequent infusions. The dose varied from
100 ml twice daily to 100 ml thrice daily based on physician
discretion. Incidence of renal recovery was deﬁned as com-
plete renal recovery (serum creatinine decreasing to prehospi-
talization baseline values), partial renal recovery (serum
creatinine decreasing but not back to prehospitalization
baseline values), and absence of renal recovery (no decrease
in serum creatinine and requirement of dialysis during hospi-
talization). Pulmonary edema was deﬁned as the presence
of bilateral inﬁltrates on CXR in the absence of clinically
suspected acute respiratory distress syndrome.
Statistical analyses
Characteristics of the study population by pulmonary edema
status were compared using Fisher’s exact test to compare
categorical variables, and unpaired t-tests were used to com-
pare continuous variables with a normal distribution. Non-
parametric variables were compared using the Wilcoxon
Rank-Sum Test. The percentage of patients with pulmonary
edema was plotted by the presence of complete or partial
renal recovery and by oliguria status at admission. To deter-
mine signiﬁcant differences across categories of renal recov-
ery and oliguria status, a chi-square test for linear trend
was used. Logistic regression models were ﬁtted to examine
the association of pulmonary edema with total albumin
infused and renal recovery status while simultaneously adjust-
ing for age, peak serum creatinine, MELD score, and oliguria
on presentation. These covariates were chosen based on a
backward selection logistic regression model which included
age, MELD score, initial serum albumin and creatinine,
peak serum albumin and creatinine, total albumin infused,
diuretic use during the ﬁrst 24 hours of admission, oliguria
during the ﬁrst 24 hours after admission, and renal recovery
status (no, partial, and complete). P<0.05 was considered
statistically signiﬁcant. Analyses were completed using
STATA/IC 13.1 (StataCorp LP, College Station, TX, USA).
Results
A total of 93 patients had clinically attributed HRS as the
etiology of ARF (HRD). The mean age of the patients was
57.9 years with a mean MELD score of 29 (range: 145–58),
Pothugunta K et al.
Codon Publications Journal of Renal and Hepatic Disorders 2017; 1(1): 5–10 6
mean serum albumin of 2.37 (range: 0.5–3.6), andmean serum
creatinine of 2.35 mg/dl (range: 0.77–12.8 mg/dl) on presenta-
tion. Oliguria (deﬁned as less than 500 ml of UOP in the ﬁrst
24 hours after admission) was present in 29% of the patients.
Renal recovery status was complete and partial in 20 and 17
patients, respectively, while 56 patients had no renal recovery.
The amount of albumin infused ranged from 300 to 600 g of
albumin in 52 patients while four patients received more
than 1000 g of albumin during the hospital course. Peak
serum albumin achieved during hospitalization ranged from
2.1 to 9.4 g/dl with a mean of 3.7 g/dl, and 35 of 93 patients
had a peak serum albumin of 4.0 g/dl or higher.
The baseline characteristics by renal recovery status are
shown in Table 1. The presence or absence of oliguria, age,
and development of pulmonary edema differed signiﬁcantly
by renal recovery status while the presenting MELD score,
serum creatinine, or the etiology of liver disease did not. Of
the 20 patients with complete renal recovery, 7 patients died
by the end of the study period, 10 were alive, and 3 received
an orthotropic liver transplant (OLT). In the partial renal
recovery group (N=17), a total of 12 patients died, four
received organ transplant (2 OLT and 2 simultaneous liver–
kidney transplants), and one patient remained alive without
dialysis at the end of the study period. Of the 56 patients
that had no renal recovery, 12 died without receiving dialysis,
one patient received a simultaneous liver–kidney transplant
and the remaining 43 required dialysis. Of the 43 patients
that required dialysis, 23 died, 4 received OLT, 5 received a
simultaneous liver–kidney transplant, and the rest remained
alive on dialysis at the end of the study period.
The risk of new onset pulmonary edema during the hospi-
talization was 47% (n=44). The baseline characteristics by
the development of pulmonary edema are shown in Table 2.
Both oliguria on presentation (15.1% vs. 43.4%, P=0.002)
and the presence of partial or complete renal recovery
(52.7% vs. 23.7%, P=0.002) differed signiﬁcantly by the devel-
opment of pulmonary edema. When stratiﬁed by renal out-
comes and oliguria, there was a statistically signiﬁcant
linear trend in the incidence of pulmonary edema (Figure 1)
by renal recovery and oliguria status (P<0.001), with the
highest risk noted in those with oliguria and no renal re-
covery (60.7%). A total of 29 patients required mechanical
Table 1. Baseline characteristics of patients with hepatorenal disorders receiving intravenous albumin (n=93)
Characteristic
Total
(N=93)
Complete renal
recovery (N=20)
Partial renal
recovery (N=17)
No renal
recovery (N=56)
Age (years) 57.9 (10.1) 54.8 (10.5) 63.5 (9.7) 57.3 (9.6)*
% Male 52.2 50 47 55
+MELD score 29.0 (14.9, 58.0) 27.7 (20.4, 35.9) 32.5 (26.7–33.1) 29.4 (24.7, 39.7)
Liver disease etiology
Alcoholic 52.7 50.5 70.0 48.2
HCV 15.1 15.1 0 19.6
% NASH 21.5 15.1 18.0 24.7
Other 10.8 19.3 12.0 7.5
Initial serum Cr (mg/dl)
(mean with SD)
2.90 (1.77) 3.49 (2.01) 3.73 (2.73) 2.44 (1.03)
Peak creatinine (mg/dl)
(mean with SD)
4.74 (2.01) 4.14 (2.06) 5.45 (2.28) 4.72 (1.88)
Oliguria 29.0% 25% 29.4% 30.4%**
Albumin baseline (g/dl)
(mean with SD)
2.37 (0.61) 2.39 (0.51) 2.49 (0.60) 2.36 (0.65)
Peak albumin (g/dl)
(mean with SD)
3.74 (0.94) 3.42 (0.57) 3.81 (0.99) 3.83 (1.02)
+Total albumin infused (g) 325 (200, 550) 350 (218.8, 531.25) 275 (170, 537.5) 325 (200, 687.5)
% Pulmonary edema 47.3 20.4 37.6 60.2**
MELD, Model for End-Stage Liver Disease; HCV, Hepatitis C Virus; NASH, Non-Alcoholic SteatoHepatitis; SD, standard deviation.
+values shown as median (interquartile range); **P<0.001 for oliguria and pulmonary edema; *P=0.02 for age.
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intubation during the hospital course of which 12 patients
had no recovery of renal function. On univariate analysis,
the presenting MELD score, serum creatinine, oliguria, and
renal recovery status showed signiﬁcant associations with
the development of pulmonary edema (Table 3). After adjust-
ment for age, and MELD score, both oliguria (3.32; 95%
conﬁdence interval [CI]: 1.12, 9.81) and no renal recovery
(3.38; 95% CI: 1.24, 9.16) were signiﬁcantly associated with
higher odds of developing pulmonary edema.
Discussion
Our study examined the incidence of new onset pulmonary
edema with albumin infusions in patients with HRD. While
traditionally HRS is subdivided into two types (14), type I
and type II, based on rapidity of deterioration of renal func-
tion, a recent consensus conference has proposed HRD as a
term to describe concurrent renal dysfunction in the setting
of advanced cirrhosis (13). We chose to use the term acute
HRD for our study as albumin infusions are not just limited
Table 2.Comparison of baseline characteristics of patients with hepatorenal disorders receiving intravenous albumin by the devel-
opment of pulmonary edema (n=93)
Characteristic No pulmonary edema (n=49) Pulmonary edema (n=44) P
Age 61.1 (10.2) 59.6 (10.6) 0.7
% Male 30.5 54.3% 0.4
MELD score 27.8 (15.6–58.0) 32.6 (14.9–51.4) 0.2
Initial serum Cr (mg/dl) 2.44 (1.03–12.84) 2.22 (0.77–5.93) 0.3
Peak creatinine (mg/dl) 4.25 (1.77–12.84) 4.98 (2.64–10.18) 0.6
% Oliguria 15.1 43.4 0.002
Initial albumin (g/dl) 2.30 (1.2–3.6) 2.35 (0.5–3.5) 0.6
Peak albumin (g/dl) 3.7 (2.1–4.51) 3.65 (2.1–9.4) 0.4
% Partial or complete renal
recovery
52.7 23.7 0.002
% Paracentesis 70.2 56.5 0.1
MELD, Model for End-Stage Liver Disease.
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Figure 1. Risk of new onset pulmonary edema stratiﬁed by renal recovery status and oliguria in 93 patients with hepatorenal dis-
orders receiving intravenous albumin. CR, complete recovery;NO, nonoliguric; NR, no recovery; O, oliguric; PR, partial recovery.
Pothugunta K et al.
Codon Publications Journal of Renal and Hepatic Disorders 2017; 1(1): 5–10 8
to type I HRS in clinical practice. Liver transplantation is the
treatment of choice for HRD but pharmacological treatment
with albumin infusions for volume replacement is also widely
recommended (1, 13–19).
Volume overload with continued albumin infusions is of
particular concern in cirrhotic patients. Although the guide-
lines from the International Club of Ascites acknowledge the
risk of pulmonary edema, the risk is considered to be low
(3). We noted a high risk of pulmonary edema among adults
with acute HRD receiving intravenous albumin, and this
risk was the highest in patients with oliguria and absence of
renal recovery. The presentingMELD score or serumalbumin
was not associated with a risk of pulmonary edema.Hence, we
postulate that new onset pulmonary edema was from volume
overload in the setting of continued albumin infusions. The
graded increase in the incidence of pulmonary edema when
stratiﬁed by the presence of oliguria or renal response to treat-
ment further supports our conclusion.
In our study, the amount of albumin infused was not asso-
ciated with renal recovery status or the development of
pulmonary edema. This could be related to the variable
response to albumin infusions based on intravascular volume
status on presentation. Almost all patients in our study did
not have invasive monitoring of hemodynamic parameters
which is the case in routine clinical practice. Also, there was
a wide variation in the total amount of albumin given per
day with the total amount of albumin infused varying
between 150 and 1100 g, with one patient having a peak
serum albumin as high as 9.4 g/dl on multiple readings during
the hospital course. A lag period between albumin infusions
and CXR ﬁndings and/or symptoms of pulmonary edema
could be a major confounder when trying to determine a cor-
relation between the amount of albumin infused and the
development of pulmonary edema.
The limitations of our study include the observational
design and the small sample size. Hemodynamic monitoring
was not performed in patients, and we do not have informa-
tion on the baseline volume status of the patients with acute
HRD. Patients were not weighed daily and so we do not
have information on change in their weight from admission
to the development of pulmonary edema. Oliguria on pre-
sentation was determined by physician documentation in
the chart and veriﬁed from the outputs documented in the
chart on admission. However, documentation of total ﬂuid
intake versus UOP may not have been accurately recorded.
Pulmonary edema was deﬁned by new CXR ﬁndings. The
dose and duration of intravenous albumin was determined
by the treating physician. Due to the small number of
cases of pulmonary edema, we could not control for a
large number of potential confounders, and residual confound-
ing is possible.
Conclusion
In our retrospective study, the risk of new onset pulmonary
edema was high in oliguric patients whose renal function
did not improve with intravenous albumin. Caution should
be exercised while giving continued albumin infusions to
patients with oliguria, and close monitoring of volume status
should be mandated to avoid the risk of pulmonary edema.
Table 3. Univariate and multivariable adjusted associations between clinical factors and pulmonary edema among adults with
hepatorenal disorders
Univariate odds ratio
(95% CI)
Multivariate odds ratio
(95% CI)
Age 0.97 (0.94, 1.02) 0.99 (0.94, 1.03)
MELD score 1.05 (0.99, 1.10) 1.04 (0.98, 1.09)
Initial serum albumin 0.77 (0.39, 1.51) —
Peak serum albumin 1.05 (0.68, 1.63) —
Total albumin infused 1.00 (0.99, 1.01) —
Use of diuretics at admission 1.39 (0.58, 3.30) —
Oliguria 5.00 (1.85, 13.53) 3.32 (1.12, 9.81)
Initial serum creatinine 0.95 (0.75, 1.21) —
Peak serum creatinine 1.45 (1.12, 1.87) 1.14 (0.83–1.54)
No renal recovery 5.18 (2.05, 13.08) 3.38 (1.24–9.16)
MELD, Model for End-Stage Liver Disease; CI, conﬁdence interval.
Variables in the multivariate analysis were selected by backward selection with all variables in univariate analysis ﬁtted in the model.
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